Crossmark

Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study

Crossref DOI link: https://doi.org/10.1186/s13014-019-1381-2

Published Online: 2019-10-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arians, Nathalie http://orcid.org/0000-0002-2389-5404
Kieser, Meinhard

Benner, Laura

Rochet, Nathalie

Schröder, Lars

Katayama, Sonja

Herfarth, Klaus

Schubert, Kai

Schneeweiss, Andreas

Sohn, Christof

Lindel, Katja

Debus, Jürgen
Funding

Funding for this research was provided by:

Deutsche Krebshilfe (109092)
License Information

Text and Data Mining valid from 2019-10-21

Version of Record valid from 2019-10-21
More Information

Article History

Received: 28 June 2019

Accepted: 12 September 2019

First Online: 21 October 2019

Ethics approval and consent to participate

: The study was approved by the local Ethics Committee of Heidelberg University. Written informed consent was obtained from each participant before entering the trial.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below